Dr. Reddy's subsidiary hits the pause button on drug development for psoriasis
A biotech subsidiary of the India-based pharma company Dr. Reddy’s Laboratories is halting the development of a psoriasis drug.
In an announcement to the National Stock Exchange of India on Friday, the biotech Aurigene Oncology posted the results of its Phase II study of the oral candidate AUR101 in patients with moderate to severe plaque psoriasis.
The 128-person study, dubbed Indus-3, was reported to meet its primary responsibility of a psoriasis area and severity index (PASI) response at 12 weeks at the 400 mg BID dose, against the placebo. However, the primary endpoint of a PASI at 12 weeks for the 200 mg BID and 400 mg QD dosage forms was not met. As a result, Aurigene stated that it will close the clinical development of AUR101 in patients with psoriasis.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.